Pay in 4 interest-free payments of $6.43 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
Clin Ther (2017) 39(9):17809.e33
Weight loss varies by indication and dose, with approximately 15-21% reduction at higher doses in obesity trials and typically lower percentages in type 2 diabetes studies
For polycystic kidney disease, several ferroptosis-related therapeutic drugs have been validated in animal models
Seven additional Phase 3 readouts are expected this year, including the pivotal TRIUMPH-1 (general obesity) and TRIUMPH-2 (type 2 diabetes) trials
US$ 22.22
US$ 28.48
US$ 22.76
US$ 29.65
